Agenus Reports 48% 3-Year OS in Ovarian Cancer Combo
Agenus reported an estimated 48% three-year overall survival in 35 evaluable patients in its Phase 1b C-800-01 ovarian cancer cohort using botensilimab plus balstilimab.
Agenus reported an estimated 48% three-year overall survival in 35 evaluable patients in its Phase 1b C-800-01 ovarian cancer cohort using botensilimab plus balstilimab.